NECTIN4 gene – Talk Bio

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

2 weeks ago talkbio0Tagged Aktis, AKTS, Biotech IPOs, bounce, Capital Markets, CD276 gene, Eli Lilly backing, IPO, NECTIN4 gene, Neoplasms, Radiopharmaceuticals, Window (physical object)

Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026

Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev

11 months ago talkbio0Tagged Antibody-Drug Conjugates, ASCO-GU, Cancer of Neck, Clinical Trials, Corbus Pharmaceuticals, CRB-701, NECTIN4 gene, Padcev, urothelial cancer

Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025

Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates

1 year ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck, NECTIN4 gene, SKB571, TROP2

Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571